Browsing Tag
GlaxoSmithKline
25 posts
GSK dodges tariffs with a massive pricing pivot—but what’s the catch?
GlaxoSmithKline cuts drug prices in the U.S. and secures tariff relief under a new federal deal. Find out what this means for pharma's future pricing playbook.
GSK walks away from IDEAYA cancer assets: What went wrong with synthetic lethality?
GSK ends its partnership with IDEAYA on two oncology assets. Find out what this means for IDEAYA’s pipeline, stock sentiment, and future partnerships.
GSK’s B7-H3 ADC secures EU orphan drug status as it accelerates global lung cancer trials
GSK’s B7-H3-targeted ADC GSK’227 receives EU Orphan Drug Designation for small-cell lung cancer. Learn how it fits into the company’s expanding global trial program.
How AnaptysBio’s 2026 spin-off plan could reshape its pipeline, royalty flows, and stock outlook
Discover how AnaptysBio (NASDAQ: ANAB) plans to split into two focused companies to unlock hidden value and reshape its investment story.
Enanta Pharmaceuticals to reveal Phase 2b RSV trial results—can zelicapavir change treatment for high-risk adults?
Enanta Pharmaceuticals will present Phase 2b zelicapavir results in RSV high-risk adults. See why this trial matters for investors, patients, and the RSV market.
Is pharma nationalism reshaping global R&D? What GSK, Eli Lilly, and AstraZeneca are signaling to the world
GSK, Eli Lilly and AstraZeneca are reshaping global pharma strategy with massive U.S. investments—find out what this means for R&D, supply chains, and policy.
Why GSK is investing $30bn in the U.S. now—and what it means for global pharma manufacturing
GSK to invest $30B in U.S. R&D and manufacturing amid trade policy shifts—find out how this shapes global pharma supply chains and investor sentiment.
Canada approves GSK’s Arexvy vaccine for RSV protection in adults 50-59 at elevated risk
In a crucial development for public health, Health Canada has extended its approval for GlaxoSmithKline’s Arexvy vaccine to…
Pfizer to offload 540 million shares in shocking Haleon sale—What does this mean for the healthcare giant?
In a blockbuster move set to shake up the market, Pfizer has announced its plan to sell approximately…
Glenmark Pharmaceuticals gets FDA final approval for Compazine generic
Glenmark Pharmaceuticals has bagged final approval for Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg from the…